Seiichiro Katagiri

763 total citations
59 papers, 498 citations indexed

About

Seiichiro Katagiri is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Seiichiro Katagiri has authored 59 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 21 papers in Genetics and 15 papers in Molecular Biology. Recurrent topics in Seiichiro Katagiri's work include Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Seiichiro Katagiri is often cited by papers focused on Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Seiichiro Katagiri collaborates with scholars based in Japan, India and Singapore. Seiichiro Katagiri's co-authors include Kazuma Ohyashiki, Tetsuzo Tauchi, Seiichi Okabe, Yoshiyuki Takahashi, Masashi Nagano, Junko H. Ohyashiki, Tomohiro Umezu, Moritaka Gotoh, Takayuki Yoshimoto and Izuru Mizoguchi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Seiichiro Katagiri

51 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiichiro Katagiri Japan 14 207 199 116 111 74 59 498
Jochen Casper Germany 13 313 1.5× 241 1.2× 85 0.7× 139 1.3× 33 0.4× 39 701
Maria Spyropoulou‐Vlachou Greece 13 239 1.2× 189 0.9× 55 0.5× 56 0.5× 65 0.9× 26 676
Junichi Ueyama Japan 11 204 1.0× 162 0.8× 53 0.5× 54 0.5× 6 0.1× 35 545
Ruxiu Tie China 11 100 0.5× 131 0.7× 45 0.4× 21 0.2× 85 1.1× 19 381
Sarah Moore Australia 12 265 1.3× 175 0.9× 173 1.5× 74 0.7× 5 0.1× 32 563
Martin Schwonzen Germany 13 142 0.7× 106 0.5× 89 0.8× 75 0.7× 8 0.1× 27 510
Simon Bornschein Belgium 12 128 0.6× 316 1.6× 35 0.3× 100 0.9× 8 0.1× 15 665
Jenny I. O. Craig United Kingdom 9 454 2.2× 288 1.4× 207 1.8× 56 0.5× 5 0.1× 14 669
M. Brandely France 14 164 0.8× 119 0.6× 19 0.2× 36 0.3× 54 0.7× 36 760
Rikke Riisbro Denmark 11 107 0.5× 204 1.0× 55 0.5× 15 0.1× 14 0.2× 17 480

Countries citing papers authored by Seiichiro Katagiri

Since Specialization
Citations

This map shows the geographic impact of Seiichiro Katagiri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiichiro Katagiri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiichiro Katagiri more than expected).

Fields of papers citing papers by Seiichiro Katagiri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiichiro Katagiri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiichiro Katagiri. The network helps show where Seiichiro Katagiri may publish in the future.

Co-authorship network of co-authors of Seiichiro Katagiri

This figure shows the co-authorship network connecting the top 25 collaborators of Seiichiro Katagiri. A scholar is included among the top collaborators of Seiichiro Katagiri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiichiro Katagiri. Seiichiro Katagiri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Katagiri, Seiichiro, Daigo Akahane, Kunihiko Takeyama, et al.. (2025). TP53 deletion is associated with poor survival of adult ALK-positive ALCL patients receiving CHOP-based chemotherapy. Annals of Hematology. 104(3). 1801–1806. 1 indexed citations
2.
Katagiri, Seiichiro, Daigo Akahane, Yosuke Minami, et al.. (2023). Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy. OncoTargets and Therapy. Volume 16. 571–576. 1 indexed citations
3.
Yamada, Akiko, Seiichiro Katagiri, Seiichiro Yoshizawa, et al.. (2021). Epstein-Barr virus-associated post-transplant lymphoproliferative disease during dasatinib treatment occurred 10 years after umbilical cord blood transplantation. Journal of Infection and Chemotherapy. 27(7). 1076–1079. 3 indexed citations
4.
5.
Yokomizo‐Nakano, Takako, Sho Kubota, Jie Bai, et al.. (2020). Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome. Cancer Research. 80(12). 2523–2536. 14 indexed citations
6.
Katagiri, Seiichiro, Daigo Akahane, Hiroaki Fujimoto, et al.. (2018). Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma. Clinical Case Reports. 6(9). 1681–1683. 5 indexed citations
7.
Tauchi, Tetsuzo, Seiichi Okabe, Seiichiro Katagiri, Yuko Tanaka, & Kazuma Ohyashiki. (2017). Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC). Blood. 130. 1249–1249. 3 indexed citations
8.
Umezu, Tomohiro, Seiichiro Katagiri, Chiaki Kobayashi, et al.. (2017). Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. International Journal of Hematology. 105(4). 419–422. 16 indexed citations
9.
Azuma, Kenko, Tomohiro Umezu, Satoshi Imanishi, et al.. (2017). Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing. Leukemia Research. 62. 23–28. 10 indexed citations
10.
Katagiri, Seiichiro, Moritaka Gotoh, Daigo Akahane, et al.. (2016). Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation. International Journal of Hematology. 103(5). 592–595. 5 indexed citations
11.
Gotoh, Moritaka, Seiichiro Yoshizawa, Seiichiro Katagiri, et al.. (2014). A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies. Bone Marrow Transplantation. 49(7). 955–960. 2 indexed citations
12.
Ohyashiki, Junko H., Izuru Mizoguchi, Takayuki Yoshimoto, et al.. (2014). Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. Drug Design Development and Therapy. 8. 1151–1151. 21 indexed citations
13.
Yoshimoto, Takayuki, Izuru Mizoguchi, Seiichiro Katagiri, et al.. (2014). Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. OncoImmunology. 3(5). e28861–e28861. 10 indexed citations
14.
Katagiri, Seiichiro, Tetsuzo Tauchi, Seiichi Okabe, et al.. (2013). Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia. Clinical Cancer Research. 19(6). 1422–1432. 35 indexed citations
15.
Mizoguchi, Izuru, Takayuki Yoshimoto, Seiichiro Katagiri, et al.. (2013). Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Science. 104(9). 1146–1153. 29 indexed citations
16.
Okabe, Seiichi, Tetsuzo Tauchi, Yuko Tanaka, Seiichiro Katagiri, & Kazuma Ohyashiki. (2012). Effects of the Hedgehog Inhibitor GDC-0449, Alone or in Combination with Dasatinib, on BCR-ABL-Positive Leukemia Cells. Stem Cells and Development. 21(16). 2939–2948. 16 indexed citations
17.
Takahashi, Yoshiyuki, et al.. (2002). Birth of pups after transfer of mouse embryos derived from vitrified preantral follicles. Reproduction. 123(4). 593–600. 74 indexed citations
18.
19.
Furubayashi, Takayasu, H. Mizutani, Hironori Take, et al.. (1992). Impaired Suppressor Function of T Cells Induced by Autologous Mixed Lymphocyte Reaction in Patients with Idiopathic Thrombocytopenic Purpura. Acta Haematologica. 87(1-2). 32–36. 4 indexed citations
20.
Katagiri, Seiichiro, Takuro Yonezawa, Toshiharu Tamaki, et al.. (1984). Surface Expression of Human Myeloma Cells: An Analysis Using a Panel of Monoclonal Antibodies. Acta Haematologica. 72(6). 372–378. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jochen Casper Breakdown of academic impact, for papers by Maria Spyropoulou‐Vlachou Breakdown of academic impact, for papers by Junichi Ueyama Breakdown of academic impact, for papers by Ruxiu Tie Breakdown of academic impact, for papers by Sarah Moore Breakdown of academic impact, for papers by Martin Schwonzen Breakdown of academic impact, for papers by Simon Bornschein Breakdown of academic impact, for papers by Jenny I. O. Craig Breakdown of academic impact, for papers by M. Brandely Breakdown of academic impact, for papers by Rikke Riisbro
Rankless by CCL
2026